Researchers find new way to control genes often involved in cancer growth

July 8, 2016, H. Lee Moffitt Cancer Center & Research Institute
cancer
Killer T cells surround a cancer cell. Credit: NIH

Cancer is a group of more than 100 different diseases. All are driven by cells and genes that escape the normal process of division and begin their own plan to replicate in the body. Advances in genetics and molecular biology are providing researchers with better knowledge of the genetic mutations and cell alterations that can lead to cancer, and also how to utilize that information to develop preventive measures and therapies to target the diseases.

Moffitt Cancer Center, a leader in molecular cancer research, and a research team led by Jia Fang, Ph.D., assistant member of the Tumor Biology Department, has discovered a new way to control the activity of SETDB1, a that is often upregulated in cancer. Their findings have been published in the June 16 issue of Molecular Cell.

The novel mechanism to control the protein function is called monoubiquitination. Proteins can be regulated by a process called ubiquitination, in which an ubiquitin molecule is added to a protein. Ubiquitin modification can result in a number of different effects. The addition of many ubiquitin molecules can target a protein for degradation, while the addition of a single ubiquitin molecule (monoubiquitination) can lead to activation of protein signaling pathways or target other proteins for ubiquitination. Ubiquitin is usually added to a protein through an ordered series of events - activation by an E1 , conjugation by an E2 enzyme and ligation by an E3 enzyme.

SETDB1 regulates the level of DNA compaction and gene expression. When SETDB1 is active, the expression levels of target genes are repressed. Given its critical role in controlling gene expression, SETDB1 must be precisely regulated to ensure that molecular processes run properly.

Moffitt researchers performed molecular studies to show for the first time that SETDB1 is constitutively modified by a single ubiquitin molecule. The ubiquitination event is mediated directly by E1 and E2 enzymes, without the traditional involvement of an E3 enzyme. Importantly, this monoubiquitination serves as an integral part of SETDB1 to render its activity and leads to inhibition of target .

"This is the first demonstration that a constitutive monoubiquitination by an E2 enzyme complements the function of a key enzyme. These results suggest that this class of E2 enzymes is an attractive target for therapeutics," said Fang.

Explore further: Research explains the role of the gene BRCA1 in DNA repair

More information: Lidong Sun et al, E3-Independent Constitutive Monoubiquitination Complements Histone Methyltransferase Activity of SETDB1, Molecular Cell (2016). DOI: 10.1016/j.molcel.2016.04.022

Related Stories

Research explains the role of the gene BRCA1 in DNA repair

May 30, 2016
Scientists at the University of Birmingham are a step closer to understanding the role of the gene BRCA1. Changes in this gene are associated with a high risk of developing breast and ovarian cancer.

A single enzyme with the power of three could offer shortcut to therapeutic target

April 19, 2016
Researchers identified a single enzyme doing the work of a trio thought necessary to control a common cellular signaling process being pursued as a therapeutic target.

New mechanism for cancer progression discovered

November 27, 2012
The protein Ras plays an important role in cellular growth control. Researchers have focused on the protein because mutations in its gene are found in more than 30 percent of all cancers, making it the most prevalent human ...

Recommended for you

Sequencing genomes of Nigerian women could help prevent many lethal breast cancers

August 21, 2018
For the first time, DNA contributed by Sub-Saharan African women has been thoroughly evaluated with innovative genomics technology in an effort to understand the genetic bases for breast cancer in African populations.

First in-depth profile of CAR T-cell signals suggests how to improve immunotherapy

August 21, 2018
CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling ...

Scientists take step toward new, targeted lung cancer treatment

August 21, 2018
Scientists have identified a key molecular player in a subtype of lung cancer which could lead to a new way to tackle the disease, according to research published in Nature Communications.

New compound advances into Phase 1 trial for pancreatic cancer

August 21, 2018
A compound discovered at Sanford Burnham Prebys Medical Discovery Institute (SBP) has advanced into a Phase 1 trial for metastatic pancreatic cancer. Called CEND-1 (scientifically known as iRGD), the compound was exclusively ...

Simple test could identify bladder cancer patients who won't respond to immunotherapy

August 21, 2018
Patients who are unlikely to benefit from a commonly used immunotherapy for bladder cancer could be identified by a simple blood test, according to researchers at Brighton and Sussex Medical School (BSMS).

Annual pap test a 'thing of the past?'

August 21, 2018
The United States Preventive Services Task Force (USPSTF) has released new recommendations on screening for cervical cancer. These latest recommendations continue the trend of decreasing participant burden by lengthening ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.